[Results] 87 weeks, 36kg, and endpoint was the hard part
STEP. That is the whole post, but I will justify it.
Everything else people worry about in c/orforglipron is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does.
I say this having got it wrong for 23 months. My triglycerides was the thing that eventually made me pay attention, which is a stupid way to learn a lesson that was in the sidebar the whole time.
best — the order this archive was captured in
off-label use data is different from approved-indication data
Tracking number removed. It identifies both ends of a shipment.
number-needed-to-treat is the house dialect
dropout handling matters, especially on GI-heavy populations
the relative risk reduction in headlines is not the whole story
the 3 week readout is different from the 8 week readout
Not convinced. The evidence does not support that reading.
Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.
the discontinuation arms are the interesting part, not the FLOW endpoints
dropout handling matters, especially on GI-heavy populations
Small correction: the trial was 13 weeks, not 32. Does not change your point but people will quote it.
press release SURMOUNT posts must be flaired until a publication exists
number-needed-to-treat is the house dialect
Phase 2 TRIUMPH looked amazing.
Yes, exactly this, and it is the bit that took me 28 weeks to accept.
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix
SELECT reported a hazard ratio hazard ratio but the absolute event rate is what changes clinical practice.
- 1Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on…7 comments in this branch · started by u/niels_norgaard
- 2off-label use data is different from approved-indication data5 comments in this branch · started by u/iman_castellanos